share_log
Reuters ·  Apr 29 08:00
Soleno Therapeutics Inc - Planned Submission of a New Drug Application (Nda) for Dccr Remains on Track for Mid-2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment